|Table of Contents|

Establishment of paclitaxel-resistant colon cancer cell line LoVo/TAX and its drug-resistance mechanisms

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 01
Page:
4-9
Research Field:
Publishing date:

Info

Title:
Establishment of paclitaxel-resistant colon cancer cell line LoVo/TAX and its drug-resistance mechanisms
Author(s):
Guo Jiayi1; Chen Yifan2; Li Yunhong1; Zhang Min2; Zhang Yan2; Huang Weidong2
1.Ningxia Institute of Medical Sciences，Ningxia Yinchuan 750004，China；2.Basic Medical College，Ningxia Medical University，Ningxia Yinchuan 750004，China.
Keywords:
colon cancer cell; paclitaxel resistance; MRP1; MAP-Tau; CDK1
PACS:
R735.3+5
DOI:
10.3969/j.issn.1672-4992.2018.01.002
Abstract:
Objective：To explore the potential molecular mechanism of paclitaxel resistance in colon cancer with Taxol-resistant colon cancer LoVo/TAX cell line compare with its parental cell LoVo.Methods：The morphological features were observed by inverted microscope and transmission electron microscope，drug resistance of LoVo and LoVo/TAX was determined using an MTT assay，cell cycle analysis and apoptosis were determined by flow cytometry，the mRNA levels of Mdr1，Mrp1，GST-π，LRP，TopoⅡ，TUBB3，Cdk1，MAP-Tau，Bcl-2，TP53 were assessed by real time quantitative PCR，the protein expression level of MRP1，Bcl-2，TUBB3，Cdk1 and MAP-Tau were detected by Western blot.Results：The resistance of LoVo/TAX cells to Taxol was 42.32-fold than that of the original LoVo cells.It also exhibited high-level cross-resistance to Adriamycin (ADM) and 5-fluorouracil (5-FU).The proportion of cells in G2/M phase decreased significantly (P<0.05) and the apoptosis rate of LoVo/TAX cells was also decreased significantly (P<0.01) than that of LoVo cells after treated with 1.5 μmol/L Taxol for 24 h.Overexpression of MRP1，MAP-Tau and CDK1 was associated with the development of drug resistance in LoVo/TAX.Conclusion：Overexpression of the multidrug resistance-associated protein MRP1，microtubule-associated protein (MAP)-Tau and cyclin-dependent kinase 1 (CDK1) might contribute to acquired paclitaxel resistance in colon cancer cell.

References:

［1］Khanna C，Rosenberg M，Vail DM.A review of paclitaxel and novel formulations including those suitable for use in dogs［J］.J Vet Intern Med，2015，29(4)：1006-1012.
［2］Bernabeu E，Cagel M，Lagomarsino E，et al.Paclitaxel：What has been done and the challenges remain ahead［J］.Int J Pharm，2017，526(1-2)：474-495.
［3］Chung KY，Saltz LB.Adjuvant therapy of colon cancer：current status and future directions［J］.Cancer J，2007，13(3)：192-197.
［4］Zhang J，Zhao J，Zhang W，et al.Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance［J］.Int J Gynecol Cancer，2012，22(9)：1450-1456.
［5］Chen SY，Hu SS，Dong Q，et al.Establishment of paclitaxel-resistant breast cancer cell line and nude mice models，and underlying multidrug resistance mechanisms in vitro and in vivo［J］.Asian Pac J Cancer Prev，2013，14(10)：6135-6140.
［6］Teng PN，Bateman NW，Wang G，et al.Establishment and characterization of a platinum-and paclitaxel-resistant high grade serous ovarian carcinoma cell line［J］.Hum Cell，2017，30(3)：226-236.
［7］Hyuga S，Shiraishi M，Hori A，et al.Effects of Kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells［J］.Biol Pharm Bull，2012，35(10)：1729-1739.
［8］Takeda M，Mizokami A，Mamiya K，et al.The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines［J］.Prostate，2007，67(9)：955-967.
［9］Wang C，Guo LB，Ma JY，et al.Establishment and characterization of a paclitaxel-resistant human esophageal carcinoma cell line［J］.Int J Oncol，2013，43(5)：1607-1617.
［10］Xu X，Jin S，Ma Y，et al.miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting Bcl-2 expression［J］.J Mol Med (Berl)，2017，95(8)：861-871.
［11］Zhang LF，Ma XF，Zhang XP，et al.Comparison research on MDR human breast cancer cell lines induced by Adr and Tax［J］.Chinese Pharmacological Bulletin，2009，25（5）：609-613.［张莲芬，马晓峰，张小平，等.阿霉素和紫杉醇诱发的人乳腺癌耐药细胞株的比较研究［J］.中国药理学通报，2009，25（5）：609-613.］
［12］Vaidyanathan A，Sawers L，Gannon AL，et al.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells［J］.Br J Cancer，2016，115(4)：431-441.
［13］Lee JP，Hahn HS，Hwang SJ，et al.Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression［J］.J Gynecol Oncol，2013，24(3)：273-279.
［14］Wang B，Li S，Meng X，et al.Inhibition of MDR1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells［J］.Tumour Biol，2015，36(8)：6433-6443.
［15］Safinya CR，Chung PJ，Song C，et al.The effect of multivalent cations and Tau on paclitaxel-stabilized microtubule assembly，disassembly，and structure［J］.Adv Colloid Interface Sci，2016，6(232)：9-16.
［16］Choi MC，Chung PJ，Song C，et al.Paclitaxel suppresses Tau-mediated microtubule bundling in a concentration-dependent manner［J］.Biochim Biophys Acta，2017，1(1861)：3456-3463.
［17］Wu H，Huang M，Lu M，et al.Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel［J］.Cancer Chemother Pharmacol，2013，71(5)：1159-1171.
［18］Barbuti AM，Chen ZS.Paclitaxel through the ages of anticancer therapy：Exploring its role in chemoresistance and radiation therapy［J］.Cancers (Basel),2015,7(4)：2360-2371.

Memo

Memo:
宁夏高等学校科学研究项目（编号：NGY2012052）
Last Update: 2017-11-30